157 related articles for article (PubMed ID: 32059541)
1. Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth.
Ehexige E; Bao M; Bazarjav P; Yu X; Xiao H; Han S; Baigude H
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32059541
[TBL] [Abstract][Full Text] [Related]
2. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
Bastaki S; Aravindhan S; Ahmadpour Saheb N; Afsari Kashani M; Evgenievich Dorofeev A; Karoon Kiani F; Jahandideh H; Beigi Dargani F; Aksoun M; Nikkhoo A; Masjedi A; Mahmoodpoor A; Ahmadi M; Dolati S; Namvar Aghdash S; Jadidi-Niaragh F
Life Sci; 2021 Feb; 266():118847. PubMed ID: 33309720
[TBL] [Abstract][Full Text] [Related]
3. Design of Peptidomimetic Functionalized Cholesterol Based Lipid Nanoparticles for Efficient Delivery of Therapeutic Nucleic Acids.
Ehexige E; Ganbold T; Yu X; Han S; Baigude H
Molecules; 2019 Sep; 24(18):. PubMed ID: 31546908
[TBL] [Abstract][Full Text] [Related]
4. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
Li C; Han X
Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
6. Intradermal delivery of STAT3 siRNA to treat melanoma via dissolving microneedles.
Pan J; Ruan W; Qin M; Long Y; Wan T; Yu K; Zhai Y; Wu C; Xu Y
Sci Rep; 2018 Jan; 8(1):1117. PubMed ID: 29348670
[TBL] [Abstract][Full Text] [Related]
7. Effective Skin Cancer Treatment by Topical Co-delivery of Curcumin and STAT3 siRNA Using Cationic Liposomes.
Jose A; Labala S; Ninave KM; Gade SK; Venuganti VVK
AAPS PharmSciTech; 2018 Jan; 19(1):166-175. PubMed ID: 28639178
[TBL] [Abstract][Full Text] [Related]
8. Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma.
Labala S; Jose A; Venuganti VV
Colloids Surf B Biointerfaces; 2016 Oct; 146():188-97. PubMed ID: 27318964
[TBL] [Abstract][Full Text] [Related]
9. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.
Alshamsan A; Hamdy S; Samuel J; El-Kadi AO; Lavasanifar A; Uludağ H
Biomaterials; 2010 Feb; 31(6):1420-8. PubMed ID: 19913908
[TBL] [Abstract][Full Text] [Related]
10. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-22 attenuates double-stranded RNA-induced upregulation of PD-L1 in airway epithelial cells via a STAT3-dependent mechanism.
Seki N; Kan-O K; Matsumoto K; Fukuyama S; Hamano S; Tonai K; Ota K; Inoue H; Nakanishi Y
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):242-248. PubMed ID: 29032197
[TBL] [Abstract][Full Text] [Related]
12. Functional graphene oxide as a plasmid-based Stat3 siRNA carrier inhibits mouse malignant melanoma growth in vivo.
Yin D; Li Y; Lin H; Guo B; Du Y; Li X; Jia H; Zhao X; Tang J; Zhang L
Nanotechnology; 2013 Mar; 24(10):105102. PubMed ID: 23425941
[TBL] [Abstract][Full Text] [Related]
13. Delivery of siRNA Complexed with Palmitoylated α-Peptide/β-Peptoid Cell-Penetrating Peptidomimetics: Membrane Interaction and Structural Characterization of a Lipid-Based Nanocarrier System.
Jing X; Foged C; Martin-Bertelsen B; Yaghmur A; Knapp KM; Malmsten M; Franzyk H; Nielsen HM
Mol Pharm; 2016 Jun; 13(6):1739-49. PubMed ID: 26654841
[TBL] [Abstract][Full Text] [Related]
14. [Blockade of programmed death-ligand 1 attenuates indirect acute lung injury in mice through targeting endothelial cells but not epithelial cells].
Sun B; Li X; Zheng G; Dong T; Li Y; Li H; Yan Y; Bai J; Xu S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Jan; 31(1):37-43. PubMed ID: 30707867
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.
Tang X; Rao J; Yin S; Wei J; Xia C; Li M; Mei L; Zhang Z; He Q
Eur J Pharm Sci; 2019 Jan; 127():161-174. PubMed ID: 30366077
[TBL] [Abstract][Full Text] [Related]
16. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.
Wang Y; Xu Z; Guo S; Zhang L; Sharma A; Robertson GP; Huang L
Mol Ther; 2013 Oct; 21(10):1919-29. PubMed ID: 23774794
[TBL] [Abstract][Full Text] [Related]
17. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
Wang C; Shi X; Song H; Zhang C; Wang X; Huang P; Dong A; Zhang Y; Kong D; Wang W
Biomaterials; 2021 Jan; 268():120579. PubMed ID: 33278683
[TBL] [Abstract][Full Text] [Related]
18. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells.
Sasidharan Nair V; Toor SM; Ali BR; Elkord E
Expert Opin Ther Targets; 2018 Jun; 22(6):547-557. PubMed ID: 29702007
[TBL] [Abstract][Full Text] [Related]
20. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
Hossain DM; Dos Santos C; Zhang Q; Kozlowska A; Liu H; Gao C; Moreira D; Swiderski P; Jozwiak A; Kline J; Forman S; Bhatia R; Kuo YH; Kortylewski M
Blood; 2014 Jan; 123(1):15-25. PubMed ID: 24169824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
